Clinical Scorecard: Role of Extracellular Vesicles in Atopic Dermatitis: Identifying Pathogenic Factors and Developing Therapeutic Delivery Systems

At a Glance

Key Highlights

• AD is characterized by intense pruritus and recurrent skin lesions.
• Pathogenesis involves a triple hit: barrier dysfunction, dysbiosis, and immune dysregulation.
• Extracellular vesicles (EVs) play a dual role in AD pathophysiology and treatment.
• Therapeutic EVs show potential for multipathway immunomodulation.
• Challenges include standardization of EV preparation and characterization.

Guideline-Based Recommendations

Diagnosis

• Clinical diagnosis based on symptoms and history.
• Consideration of genetic predisposition and IgE levels.

Management

• Topical corticosteroids for acute inflammation.
• Topical emollients to restore barrier function.
• Systemic immunosuppressants for moderate-to-severe cases.

Monitoring & Follow-up

• Regular assessment of skin condition and treatment response.
• Monitoring for side effects of systemic therapies.

Risks

• Potential side effects from systemic immunosuppressants.
• Risk of skin infections due to barrier dysfunction.

Patient & Prescribing Data

Individuals with moderate-to-severe Atopic Dermatitis.

Targeted biologics like Dupilumab are emerging as effective treatments.

Clinical Best Practices

• Implement long-term disease control strategies.
• Focus on relapse prevention and symptom relief.
• Utilize a multidisciplinary approach for comprehensive care.

Related Resources & Content

• Atopic Dermatitis Overview
• Extracellular Vesicles in AD